
This article was downloaded by: [University of Saskatchewan Library]

On: 13 January 2015, At: 10:30 Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered

office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



### Organic Preparations and Procedures International: The New Journal for Organic Synthesis

Publication details, including instructions for authors and subscription information:

http://www.tandfonline.com/loi/uopp20

# A Practical Synthesis of $\alpha$ -Asarone via lodine-catalyzed Isomerization of $\alpha/\beta$ -Asarone

Guangyu Xu a , Chang Liu a , Wei Zhang b & Gaolei Zuo a

<sup>a</sup> College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha, PR, China

<sup>b</sup> College of Medicine , Hunan Normal University , Changsha, PR, China

Published online: 22 Apr 2009.

To cite this article: Guangyu Xu , Chang Liu , Wei Zhang & Gaolei Zuo (2009) A Practical Synthesis of  $\alpha$ -Asarone via lodine-catalyzed Isomerization of  $\alpha/\beta$ -Asarone, Organic Preparations and Procedures International: The New Journal for Organic Synthesis, 41:2, 152-155, DOI: 10.1080/00304940902802099

To link to this article: <a href="http://dx.doi.org/10.1080/00304940902802099">http://dx.doi.org/10.1080/00304940902802099</a>

#### PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <a href="http://www.tandfonline.com/page/terms-and-conditions">http://www.tandfonline.com/page/terms-and-conditions</a>

152 Xu et al.

- 5. M. Lebedev and M. Erman, Tetrahedron Lett., 43, 1397 (2002).
- 6. F. Rahm, A. Fischer and C. Moberg, Eur. J. Org. Chem., 4205 (2003).
- 7. M. Falorni, L. Lardicci and G. Giacomelli, J. Org. Chem., 54, 2383 (1989).
- 8. E. Cesaroti, H. Kagan, R. Goddard and D. Kruger, J. Organometall. Chem., 162, 279 (1978).
- 9. H. Adolfsson, K. Nordstrom, K. Warnmark and C. Mobert, Tetrahedron Asymm., 7, 1967 (1996).
- 10. A. Fischli and P. Muller, Helv. Chim. Acta, 63, 1619 (1980).
- M. Yamashita, Y. Soeda, N. Suzuki, M. Yamada, K. Tsuenkawa, T. Oshikawa and S. Inokawa, Bull. Chem. Soc. Jpn, 56, 1871 (1983).

Organic Preparations and Procedures International, 41:152-155, 2009

Copyright © Taylor & Francis Group, LLC

ISSN: 0030-4948 print

DOI: 10.1080/00304940902802099



# A Practical Synthesis of $\alpha$ -Asarone *via* Iodine-catalyzed Isomerization of $\alpha/\beta$ -Asarone

Guangyu Xu,<sup>1</sup> Chang Liu,<sup>1</sup> Wei Zhang,<sup>2</sup> and Gaolei Zuo<sup>1</sup>

<sup>1</sup>College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha, P. R. China

<sup>2</sup>College of Medicine, Hunan Normal University, Changsha, P. R. China

 $\alpha$ -Asarone (1), isolated from the *Guatteria guameri* plant growing in southeast Mexico, is reported to be an anti-platelet and hypolipidemic agent. <sup>1,2</sup> In addition, it is known to have sedating, neuroleptic, spasmolytic, anti-ulcerogenic and anti-atherogenic activity. <sup>3,4</sup> Due to its low availability from natural sources, several synthetic approaches have been developed for  $\alpha$ -asarone (*trans*-isomer, 1), which involve Grignard, Wittig, Aldol-Grob, Friedel-Crafts reactions. <sup>5–9</sup> However, in the above methods, some of the unwanted toxic  $\beta$ -asarone (*cis*-isomer, 2) was always formed, along with the desired  $\alpha$ -asarone, which is difficult to separate by column chromatography due to similarities in  $R_f$  values.  $\beta$ -Asarone can be converted to  $\alpha$ -asarone by fusion with KOH in good yield. <sup>10</sup> However, this reaction requires an excess amount of KOH (37 equiv.) and high temperature (200–220°C). Selenium dioxide, which can effectively convert  $\beta$ -asarone to  $\alpha$ -asarone, <sup>10</sup> is not a good choice due to its toxicity. A recently developed palladium (II) catalyzed isomerization of *cis*-arylalkenes can also be applied to the preparation of  $\alpha$ -asarone, <sup>11,12</sup> however, industrial applications of this reaction on synthesis of  $\alpha$ -asarone are challenging because the catalyst is expensive,

Submitted August 29, 2008.

Address correspondence to Guangyu Xu, Hunan Normal University, College of Chemistry and Chemical Engineering, Changsha 410081, P. R. China. E-mail: gyxu@hunnu.edu.cn

and difficult to recycle. Moreover, traces of palladium are difficult to remove from the product. It would, therefore, be useful to develop a reliable, mild, economical, and environmentally friendly method for the conversion of  $\beta$ -asarone to  $\alpha$ -asarone. We present herein a facile synthesis of  $\alpha$ -asarone *via* iodine-catalyzed isomerization of  $\alpha/\beta$ -asarone mixture (*Scheme 1*).

#### Scheme 1

Reagents and conditions: i. CH<sub>3</sub>CH<sub>2</sub>PPh<sub>3</sub> Br<sup>-</sup>, dioxane, K<sub>2</sub>CO<sub>3</sub>, reflux, 24 hours; ii. 0.1% I<sub>2</sub>, EtOAc, rt, 5 hours.

Although the iodine catalyzed isomerization of *cis*-stilbenes to *trans*-stilbenes has been reported,  $^{13-15}$  to the best of our knowledge, the successful iodine catalyzed inversion of  $\beta$ -asarone has not been described. We thus investigated the effect of solvent and the amount of iodine on the isomerization of a 43:57 mixture of  $\alpha$ - and  $\beta$ -asarone obtained as previously described.  $^{12}$ 

It was found that the use of solvents such as toluene, chloroform, dioxane, ethyl acetate, and benzene all led to good selectivity (97/3 mixture) in 1 hour or less using 2 mol% iodine at room temperature; the best yields (79%) were obtained in toluene and ethyl acetate. The use of 0.1 mol% of iodine in ethyl acetate at room temperature for 5 hours gave the best results (97/3 [by GC] and 92% yield [based the total amount of the two isomers]). The fact that the isomerization may be performed in the dark (7 hours) makes it suitable for large scale production. The two by-products formed in the isomerization reaction were isolated by silicon gel column chromatography using hexane/ethyl acetate (4/1) as eluent, and identified by NMR and MS as dimer 3 and trimer 4. By-product 3 had been reported previously. 12

In summary, a simple and practical catalytic process for the preparation of pure  $\alpha$ -asarone has been demonstrated. The mild conditions, operational simplicity, low toxicity, and low loading of catalyst make this process a more useful and practical alternative to the conventional methods for the acquisition of  $\alpha$ -asarone from abundantly available but toxic  $\beta$ -asarone in nature.

154 Xu et al.

#### **Experimental Section**

All reagents and solvents were obtained from commercial suppliers and used without further purification. Mps were determined on a Büchi 510 melting point apparatus and are uncorrected. GC was performed on an Agilent 6890N with a capillary column (0.32 mm  $\times$  32 m) immobile with liquid SE-30 (column flow rate 1.3 mL/min, vaporizer temperature 240°C, column temperature 170°C, detector temperature 250°C). The purity of product was determined by HPLC: column, SB-C18 column, 250 mm  $\times$  4.6 mm, 5  $\mu$ ; mobile phase, 10% CH<sub>3</sub>CN in water; flow rate 1.0 mL/min; detection, 258 nm. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded in CDCl<sub>3</sub> on a Brucker-400 NMR spectrometer. EIMS were determined with a HP5989B mass spectrometer.

#### Preparation of α-Asarone

In a 10-L glass vessel, a solution of  $\alpha/\beta$ -asarone mixture (1.10 kg, 5.29 mol, 97.1% purity) in 5.5 L of ethyl acetate was added 1.34g of I<sub>2</sub> (5.29 mmol), and the resulting solution was stirred at room temperature for 5 hours, after which the solution was washed with 1% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (2 × 500 ml) to destroy the remaining iodine. The organic phase was washed with water and concentrated to give a pale yellow oil. The residue was dissolved in 1.5 L of hot aq. EtOH solution (7:3 EtOH-water) then cooled to 0°C to afford 0.87 kg (81%) of 99.1% pure (HPLC) of  $\alpha$ -asarone as a white solid, mp. 61.5–62.1°C, *lit.*<sup>5</sup> 62–63°C.  $\beta$ -Asarone and other impurities were present in less than 0.5%.

## 2,3-Dihydro-4,5,7-trimethoxy-3-(2,4,5-trimethoxyphenyl)-1-(3-(2,4,5-trimethoxyphenyl)pentan-2-yl)-2-methyl-1H-indene (4)

White solid (from EtOH), mp.  $132.0-135.2^{\circ}$ C, isolated by chromatography on silica gel (4:1 hexane-ethyl acetate). <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>):  $\delta$  0.58 (t, 3 H, J = 9.6 Hz, CH<sub>3</sub>), 0.63 (d, 3 H, J = 9.6 Hz, CH<sub>3</sub>), 1.66 (d, 3 H, J = 8.8Hz, CH<sub>3</sub>), 1.43 (m, 1 H, CH), 1.73 (m, 2 H, CH<sub>2</sub>), 2.21 (m, 1 H, CH), 2.83 (dd, 1 H, J = 5.6, 7.2 Hz, CH), 3.20 (m, 1 H, CH), 3.44 (s, 3 H, OCH<sub>3</sub>), 3.61 (s, 3 H, OCH<sub>3</sub>), 3.73 (s, 3 H, OCH<sub>3</sub>), 3.77 (s, 3 H, OCH<sub>3</sub>), 3.79 (s, 3 H, OCH<sub>3</sub>), 3.86 (s, 3 H, OCH<sub>3</sub>), 3.86 (s, 3 H, OCH<sub>3</sub>), 3.88 (s, 6 H, 2 × OCH<sub>3</sub>), 4.21 (d, 1 H, J = 5.2 Hz, CH), 6.40 (s, 1 H, ArH), 6.43 (s, 1 H, ArH), 6.48 (s, 1 H, ArH), 6.55 (s, 1 H, ArH), 6.59 (s, 1 H, ArH). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  12.4, 14.9, 21.0, 26.2, 42.1, 49.3, 49.6, 53.1, 55.1, 56.0, 56.2, 56.4, 56.5, 56.5, 56.6, 56.7, 60.0, 96.5, 97.7, 97.9, 113.0, 125.2, 126.7, 127.0, 139.7, 139.9, 142.5, 142.8, 147.0, 147.5, 151.2, 151.8, 152.4, 152.8; MS (ESI): [M+Na] + 647.3.

Anal. Calcd. for C<sub>36</sub>H<sub>48</sub>O<sub>9</sub>: C, 69.21; H, 7.74. Found: C, 69.09; H, 7.88.

#### Acknowledgment

We thank the National Natural Science Foundation of China (No. 20602010) and Hunan Provincial Natural Science Foundation of China (No. 06JJ50024) for financial support.

#### References

1. A. Hernandez, M. Lourdes Lopez, G. Chamorro and T. Mendoza-Figueroa, *Planta Med.*, **59**, 121 (1993).

- F. Diaz, H. Munoz, F. Labarrios, G. Chamorro, M. Salazar, M. E. Morelos and J. Tamariz, Med. Chem. Res., 3, 101 (1993).
- 3. M. K. Menon and P. C. Dandiya, J. Pharm. Pharmacol., 9, 170 (1967).
- L. F. Belova, S. D. Alibekov, A. I. Baginskaya, S. Y. Sokolov, G. V. Pokrovskaya, V. A. Stikhin, T. Trumpe and T. I. Gorodnyuk, *Farmakol.-Toksikol.*, 48, 17 (1985); *Chem. Abs.* 104, 28405 (1986).
- F. Diaz, L. Contreras, R. Flores, J. Tamariz, F. Labarrios, G. Chamorro and H. Munoz, Org. Prep. Proced. Int., 23, 133 (1991).
- 6. J. Mulzer and O. Lammer, Angew. Chem. Int. Ed., 22, 628 (1983).
- 7. A. Sharma, B. P. Joshi and A. K. Sinha, Bull. Chem. Soc. Jpn, 77, 2231 (2004).
- 8. B. P. Joshi, A. Sharma and A. K. Sinha, *Tetrahedron*, **61**, 3075 (2005).
- 9. Z. Wang, L. Jiang and X. Xu, Youji Huaxue, 10, 350 (1990); Chem. Abs. 114, 5926 (1991).
- 10. B. S. Rao and K. Subramaniam, J. Chem. Soc., 1338 (1937).
- 11. J. Yu, M. J. Gaunt and J. B. Spencer, J. Org. Chem., 67, 4627 (2002).
- 12. G. Xu, Y. Zhou, G. Zuo and Y. Jiang, Org. Prep. Proced. Int., 39, 514 (2007).
- K. Gaukroger, J. A. Hadfield, L. A. Hepworth, N. J. Lawrence and A. T. McGown, *J. Org. Chem.*, 66, 8135 (2001).
- 14. M. A. Ali and Y. Tsuda, Chem. Pharm. Bull., 40, 2842 (1992).
- 15. A. R. Battersby and I. A. Greenock, J. Chem. Soc., 2592 (1961).